On-Site Clinical/Translational Trials

Research Match, funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, is a quick and simplified way to search the studies available on ClincalTrials.gov.

The following clinical/translational trials are active at the Boston-Providence clinical sites of the ILD Collaborative.

Antimicrobial Therapy Strategy Using Pragmatic Design in IPF

This study is a randomized, unblinded clinical trial to evaluate the relationship between long term antimicrobial therapy and a decrease in hospital visits for respiratory problems in subjects with idiopathic pulmonary fibrosis (IPF).

Biorepository for ILDs

This is an MGH-based bioregistry to collect/store samples from patients with ILD for future research.

Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease

This is a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with progressive fibrosing interstitial lung disease (PF-ILD).

Gadofosveset-enhanced Lung MRI to Assess Disease Activity in Fibrotic ILD

This is an imaging study that uses contrast-enhanced MRI to assess fibrosis in patients with particular types of ILD

Innate Immunity in IPF

This translational study uses bronchoscopy to investigate how certain cells in the lung contribute to the development of pulmonary fibrosis.

Lebrikizumab in Patients with IPF

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy or as combination therapy with pirfenidone background therapy in patients with idiopathic pulmonary fibrosis. Patients will be randomized to receive either lebrikizumab or placebo subcutaneously (SC) every 4 weeks.

Pulmonary Fibrosis Foundation Patient Registry (PFFR)

The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US. The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of well-characterized patients with interstitial lung disease (ILD) for participation in retrospective and prospective research.

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

This study is a randomized, double-blind, placebo controlled trial to evaluate the safety and efficacy of Inhaled Treprostinil administered through 20 weeks to subjects with pulmonary hypertension due to parenchymal lung disease.